NSW Pharmaceutical Science Group

The NSW Pharmaceutical Science Group was established in 1959 to “promote the dissemination and exchange of scientific and technical knowledge, particularly related to the Pharmaceutical Sciences”.

The Group has pursued this objective by the regular organisation of seminars with a panel of expert presenters. The presentations address specific topics or themes as variously applying to production, quality assurance, laboratory, regulatory and R&D of therapeutic goods.

 

Upcoming events

 

Seminar - Update to Code of GMP to PIC/S version 16

Wednesday April 3

See 'Schedule' below for link to registration and description or click here

Past Events

Expand to view available recordings and presentations

Expand AllCollapse All

  •  Vaccine Technologies Update - Wednesday 14 June 2023
  • Hybrid Audits - Thursday 1 December 2022
    • Matthew Bugg, Quality Manager, Australia & New Zealand, BeiGene
    • Click here to see the webinar recording
  • Establishing and Maintaining Data Integrity - Tuesday 25 October 2022
  • Clinical Trials – Expertises, Resources, Collaborative Partnerships and Product Supply
    Wednesday, 5 October 2022
  • PSG NSW Presents Building the RNA Ecosystem July 2022
  • Preservatives and Preservatives efficacy Seminar March 2022
  • Therapeutic Goods Labelling - Data Coding and Serialisation November 2021
  • Drug Delivery for the Treatment of Children's Cancer September 2021

    • Presenter : Prof. Maria Kavallaris AM, Founding Director, the Australian Centre for NanoMedicine, UNSW Sydney and Head, Translational Cancer Nanomedicine, Children’s Cancer Institute.

    • Click here to see webinar recording 

  • Delivery system for mRNA Covid 19 vaccine  Virtual Event On Wednesday  February 2021

    • Presenter:- Dr Andrew Geall, CEO RNA Consulting, LLC and Chief Scientific Officer of Precision NanoSystems Inc. (PNI)

      Click here to download presentation 

  • Elucidating Vaccine Formulation Stability May 2021 Webinar
  • Ingredient Supply and Change of Sources for Medicine Manufacture Monday  December 2020

    • Presentation 1 :- ARTG Variations to support market supply: TGA’s experience with prescription medicines during COVID-19

      Presentation 2: Supply Specifications

      David Edmonds, Former Principal CMC Consulting

      Presentation link Supply and specifications DE

       

      Presentation 3 :- 6 Months on – lessons learned and the future - Perspective from a Life Science industry supplier & leader: Merck

      Rebecca Lee, ANZ Managing Director, Merck

      Click here to download presentation 

      Click here to see webinar recording

  • Aspects of the Science of COVID-19 – Treatment Virtual Event On Thursday October 2020

    • 1.) COVID-19: Developing Vaccines at Pandemic Speed

    • ----- ----- Natalie Kahwajy, Senior Pharmacist (Antimicrobial Stewardship), Bankstown-Lidcombe Hospital

    • 2.) COVID-19: Treatment: Dexamethasone

    • ----- Ms Renee Faraj - Senior Regulatory Affairs Associate

    • 3.)COVID-19: Treatment: Remdesimir

    • ----- -----Prof Jan-Willem Alffenaar, Chair of Clinical Pharmacy, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy and Westmead Hospital

      • Recording available here

  • Remote auditing - Impact of Covid-19 restrictions on manufacturers and test laboratories September 2020

    • Webinar moderator and host:              

    • 1.) Remote auditing – from TGA MQB perspective

    • ----- ----- Ms Lynn Talomsin, Senior Inspector/Technical Specialist, Manufacturing Quality Branch, TGA

    • 2.) Remote auditing – from an auditee perspective

    • ----- Ms Melanie Richter, Quality Compliance Specialist, AstraZeneca

    • 3.) Auditing and other GMP experiences in the Covid-19 era – US perspective

    • ----- -----Ms Maxine Fritz, Executive Vice President, Pharmaceutical Services, NSF International

      • Recording available here

      NOTE:- The TGA presentation is unavailable on this site and has yet to be posted on the TGA website.

      Click here to Download AZ Remote Audits (RACI)

      Click here to Download NSF - Consulting Issues during Covid-19

  • Aspects of the Science of COVID-19 (3) - Vaccines  - Virtual Event July 2020

    • Webinar moderator and host:  

    • Mrs Niesha Davis, RACI Pharmaceutical Science Group (NSW) Committee and Learning and Development, Technical Manager, AstraZeneca

    • 1.) COVID-19: Developing Vaccines at Pandemic Speed

    • ----- Prof Trent Munro, Senior Group Leader, The Australian Institute for Bioengineering and Nanotechnology

    • 2.) Steps for vectored vaccines as solutions to rapid development of vaccines

    • ----- Dr Paul Howley, Managing Director, Vaxmed Pty Ltd

      • Recording available here


  • Aspects of the Science of COVID-19 (1) Virtual Event  May 2020

    • 1.) Medicinal Chemistry - How do antiviral drugs work? Are there any antiviral drugs for COVID-19?

    • -----  Dr Derek Lowe, Director in Chemical Biology Therapeutics, Novartis Institutes for BioMedical Research

    •  

      2.)Photochemistry of nucleic acids - Why does UV exposure destroy COVID-19

    • ---- A/Prof Tak Kee, Department of Chemistry, University of Adelaide

      Recording available here


  • How is the Pharmaceutical sector dealing with COVID-19  Virtual Event  April 2020

    • 1.) Laboratory perspective.   -----  Alan Doughty, CEO Chemika

      2.)Perspective from a Life Science industry supplier & leader: Merck. ---- Rebecca Lee, ANZ Managing Director, Merck

      3.) Medicine manufacturer’s Perspective.  ---- Gary Lay, Procurement manager, AstraZeneca

      • Recording available here

Vaccine Technologies Update - Wednesday 14 June 2023 Towards distributed manufacture of nanomedicines: Dr Dai Hayward, CEO Micropore Technologies (UK) Recent developments in RNA R&D and manufacturing in NSW: Prof Pall Thordarson, Director, RNA Institute UNSW Click here to see the seminar recording

Schedule

Event
There are no records.

Committee

Position
Data pager
Data pager
12
Page size:
 30 items in 2 pages
Show all 30
Chair - Mr Scott Colbourne
Chair - Mr Scott Colbourne
Secretary - Mr Scott Colbourne
Secretary - Mr Scott Colbourne
Treasurer - Mr David Edmonds
Treasurer - Mrs Noor Salman
Committee Member - Caroline D'Cruz
Committee Member - Mrs Niesha Davis
Committee Member - Ms Ivon Diaz
Committee Member - Ms Ivon Diaz
Committee Member - Mr David Edmonds
Committee Member - Dr Sviatoslav Eliseenko
Committee Member - Ms Annette Fordham
Committee Member - Ms Annette Fordham
Committee Member - Dr William Glover
Committee Member - Dr WILLIAM GLOVER
Committee Member - Dr Chen Lim
Committee Member - Dr Chen Lim
Committee Member - Dr Chen Lim
Committee Member - Dr Jurgen Lindner

Become Connected

 

If you would like get connected with NSW Pharm Group please contact us

 

  Contact us

 

Article: Regulatory and Other Requirements in Drug Development

  

David Edmonds, December 2019.

 

This article describes how, in conjunction with good and comprehensive science, a knowledge of TGA/Regulatory requirements and guidelines at the earliest stages of drug discovery and development should enhance the quality of the drug development.

 

The article can be downloaded here.